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Research
Accumulating evidence indicates that can-
cer stem cells (CSCs) probably arise from 
normal stem cells (NSCs), or partially differ-
entiated progenitor cells, and that CSCs are 
likely the driving force in tumor initiation, 
growth, and progression (Pardal et al. 2003; 
Reya et al. 2001). This developing theory is 
compelling because CSCs and NSCs share 
key characteristics, including the capacity for 
limitless self-renewal, which normally allows 
pluri  directional replenishment via differen-
tiation but during oncogenesis contributes 
to heterogeneous aberrant cell overgrowth 
(Pardal et al. 2003). Moreover, NSCs are 
conditionally immortal and generally thought 
to be innately resistant to most toxic insults, 
likely facilitating survival selection and accu-
mulation of molecular lesions required for 
acquired malignant pheno  type, consistent 
with the multi  step carcinogenesis model 
(Vogelstein and Kinzler 1993). Although 
CSCs share characteristics with tissue-con-
cordant NSCs, they display dys  regulated self-
renewal (Bonnet and Dick 1997; Pardal et al. 
2003; Ponti et al. 2005; Reya et al. 2001). 
Like NSCs, CSCs often form free-floating 
“spheres” of viable cells in vitro (Dontu et al. 
2003; Ghods et al. 2007; Ponti et al. 2005; 
Tokar et al. 2005). Although assumed, proof 
of the direct emergence of epithelial CSCs 
from an NSC population is not available, 
and the identity of the cells that acquire the 
molecular lesions initiating chemical carcino-
genesis remains undefined (Perez-Losada and 
Balmain 2003). Typically, to date, CSCs have 
been isolated from advanced tumors based 
on stem cell (SC)-like characteristics (Al-Hajj 
et al. 2003; Bonnet and Dick 1997; Ponti 
et al. 2005; Singh et al. 2004), rather than 
contemporaneously with carcinogenic ini-
tiation. Defining the role of CSCs in this pri-
mary triggering event is critical to a complete 
understanding of oncogenesis.
Inorganic arsenic is a widely distributed, 
naturally occurring environmental contami-
nant affecting tens of millions of people world-
wide [International Agency for Research on 
Cancer (IARC) 2004]. Human or rodent arse-
nic exposure causes various urogenital system 
(UGS) cancers, including urinary bladder and 
kidney cancer (IARC 2004; Waalkes et al. 
2007). Evidence in human populations in 
parts of Asia, the United States, and Australia 
exposed to arsenic suggests that the metalloid 
can target the prostate during arsenic-induced 
carcinogenesis (Benbrahim-Tallaa and Waalkes 
2008); in vitro, inorganic arsenic causes malig-
nant transformation of various cells, including 
human prostate cells (Achanzar et al. 2002; 
Benbrahim-Tallaa and Waalkes 2008). Arsenic 
also has trans  placental carcinogenic activity 
in mice (Waalkes et al. 2007) and possibly 
in humans (Smith et al. 2006), with targets 
within the UGS (Waalkes et al. 2007). Because 
of relative fetal abundance and their role in 
organogenesis and differentiation, SCs appear 
to be key targets in trans  placental carcino-
genesis (Anderson et al. 2000) and are likely 
targets in trans  placental arsenic carcino  genesis 
(Waalkes et al. 2008). Arsenic disrupts human 
and rodent skin SC dynamics in vivo and 
in vitro, eventually resulting in SC/CSC over-
abundance (Patterson and Rice 2007; Waalkes 
et al. 2008), an event probably significant to 
skin cancer develop  ment (Waalkes et al. 2008). 
Although arsenic is unequivocally carcinogenic, 
the mechanisms involved, including the precise 
target cells, remain enigmatic.
Leukemia SCs (LSCs) can be forced to 
arise from hematopoietic SCs (HSCs) after 
molecular manipulations of leukemogenesis 
genes (Krivtsov et al. 2006; Yilmaz et al. 2006; 
Zhang et al. 2006). However, it is unclear 
if human epithelial CSCs arise in a fashion 
similar to LSCs or if chemical carcinogens 
act through an attack on NSCs. Compared 
with other known carcinogens, a model pros-
tate epithelial NSC population possesses a 
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Ba c k g r o u n d: Inorganic arsenic is a ubiquitous environmental carcinogen affecting millions of 
people worldwide. Evolving theory predicts that normal stem cells (NSCs) are transformed into 
cancer stem cells (CSCs) that then drive oncogenesis. In humans, arsenic is carcinogenic in the uro-
genital system (UGS), including the bladder and potentially the prostate, whereas in mice arsenic 
induces multi  organ UGS cancers, indicating that UGS NSCs may represent targets for carcino  genic 
initiation. However, proof of emergence of CSCs induced by arsenic in a stem cell population is not 
available.
Me t h o d s : We continuously exposed the human prostate epithelial stem/progenitor cell line 
WPE-stem to an environmentally relevant level of arsenic (5 µM) in vitro and determined the 
acquired cancer phenotype. 
re s u l t s: WPE-stem cells rapidly acquired a malignant CSC-like phenotype by 18 weeks of exposure, 
becoming highly invasive, losing contact inhibition, and hyper  secreting matrix metalloproteinase-9. 
When hetero-transplanted, these cells (designated As-CSC) formed highly pleomorphic, aggressive 
tumors with immature epithelial- and mesenchymal-like cells, suggesting a highly pluripotent cell 
of origin. Consistent with tumor-derived CSCs, As-CSCs formed abundant free-floating spheres 
enriched in CSC-like cells, as confirmed by molecular analysis and the fact that only these floating 
cells formed xeno  graft tumors. An early loss of NSC self-renewal gene expression (p63, ABCG2, 
BMI-1, SHH, OCT-4, NOTCH-1) during arsenite exposure was sub  sequently reversed as the tumor 
suppressor gene PTEN was progressively suppressed and the CSC-like phenotype acquired.
co n c l u s i o n s: Arsenite transforms prostate epithelial stem/progenitor cells into CSC-like cells, 
indicating that it can produce CSCs from a model NSC population.
key w o r d s : arsenic, cancer stem cells, malignant transformation, prostate cancer, stem cells. Environ 
Health Perspect 118:108–115 (2010).  doi:10.1289/ehp.0901059 available via http://dx.doi.org/ 
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remarkable survival selection advantage toward 
arsenic over their differentiated isogenic 
counter  parts (Tokar EJ, Waalkes MP, unpub-
lished data), which would afford perpetuation 
but continued targeting during arsenic insult. 
Thus, we tested the hypothesis that arsenic 
targets prostate SCs as a central event in onco-
genesis. For this, we selected the human SC/
progenitor line WPE-stem derived from its 
parental, heterogeneous mature prostate line, 
RWPE-1, originally derived from normal pros-
tate epithelium (Bello et al. 1997). WPE-stem 
cells have well-defined prostate SC/progenitor 
cell characteristics, including high p63 (tumor 
protein p63) and keratin 5/14 expression, and 
low androgen receptor, prostate-specific andro-
gen, and K18 (keratin 18) expression (Tokar 
et al. 2005). WPE-stem cells form free-float-
ing spheres (prostaspheres) in culture and have 
a high proliferation rate and relatively high 
colony-forming ability in agar (Tokar et al. 
2005), typical NSC charac  teristics (Dontu 
et al. 2003; Ghods et al. 2007; Ponti et al. 
2005). WPE-stem cells also highly express the 
prostate SC markers ABCG2 [ATP-binding 
cassette, sub  family G (WHITE), member 2] 
and BMI-1 [BMI1 polycomb ring finger 
oncogene] [see Supplemental Material, Figure 
1, available online (doi:10.1289/ehp.0901059.
S1 via http://dx.doi.org/)]. We used arsenic 
at a concentration that approximates levels 
in drinking water in areas where arsenico  sis 
is common (Pi et al. 2002); and cells were 
exposed continuously, consistent with human 
exposure.
Materials and Methods
Cells, culture conditions, and arsenite expo-
sure. RWPE-1 is a human papillomavirus 
(HPV)-18–immortalized, non  tumorigenic, 
prostate epithelial cell line derived from nor-
mal adult human prostate (Bello et al. 1997). 
WPE-stem cells were isolated from RWPE-1 
cells by single-cell dilution cloning, are non-
tumorigenic, and have extensive SC/  progenitor 
cell characteristics [Tokar et al. 2005; see also 
Supplemental Material, Figure 1 and Table 1 
(doi:10.1289/ehp.0901059.S1)], making them 
a good model for NSCs. Cells were maintained 
as previously described (Tokar et al. 2005), 
passaged once weekly (pre  confluence), con-
tinuously exposed to a non  toxic arsenic con-
centration (5 µM, as sodium arsenite; Sigma, 
St. Louis, MO) for up to 18 weeks, and com-
pared with unexposed passage-matched con-
trols. Three separate flasks for each treatment 
were maintained.
In vitro transformation. We assessed 
in vitro biomarkers of carcinogenic trans-
formation every 3 weeks. Secreted matrix 
metalloproteinase-9 (MMP-9) activity was 
examined using conditioned medium as 
previously described (Tokar et al. 2005). 
Colony-forming efficiency (CFE) in soft agar, 
performed as previously described (Tokar et al. 
2005), was used to assess acquired malignant 
phenotype. CFE also correlates with NSC 
or CSC phenotype (Stingl et al. 2006). We 
examined cellular invasiveness, another com-
mon characteristic of malignant cells, using a 
modified Boyden chamber invasion assay as 
described by Bello et al. (1997). When in vitro 
biomarkers of acquired cancer phenotype 
became sufficiently positive, in vivo xeno  graft 
studies were performed to establish malignant 
transformation.
Free-floating sphere formation. Free-
floating spheres of viable cells in culture are a 
characteristic of SCs and CSCs (Dontu et al. 
2003; Ghods et al. 2007; Ponti et al. 2005; 
Tokar et al. 2005). To examine effects of 
arsenic on sphere formation, we plated cells 
(7.5 × 103) in T-75 flasks; cells were then 
grown for 10 days and fed every 48 hr. Total 
spheres were then counted.
Formation of branched ductal-like struc-
tures in Matrigel. Free-floating spheres were 
collected from flasks and dissociated into sin-
gle-cell suspensions by pipette trituration then 
passage through a 40-µm cell strainer (BD 
Biosciences, San Jose, CA). Cells were sus-
pended in 250 µL Matrigel (BD Biosciences) 
in 48-well plates and placed in incubators for 
24 hr. Matrigel was then covered with 300 µL 
growth medium, which was changed every 
48 hr. Images were taken 2 weeks later.
Stem cell/differentiation biomarker expres-
sion during transformation. Total RNA was 
collected using TRIzol reagent (Invitrogen, 
Carlsbad, CA) and purified with RNeasy 
Mini Kit columns (Qiagen, Valencia, CA) 
according to the manufacturer’s protocol, and 
transcribed with MuLV (Moloney murine leu-
kemia virus) reverse transcriptase and oligo-dT 
primers. Primers were designed with ABI 
Primer Express software (version 2.0; Applied 
Biosystems, Foster City, CA). We used SYBR 
Green Master Mix (ABgene, Rockford, IL) 
for real-time PCR (polymerase chain reaction) 
analysis. Cycle times were normalized with 
β-actin and glyceraldehyde-3-phosphate from 
the same sample and normalized to passage-
matched controls. Genes examined included 
p63 [tumor protein p63 (TP63)], BMI-1, 
ABCG2, SHH (sonic hedgehog), OCT-4 
[POU class 5 homeobox 1 (POU5F1)], 
NOTCH-1 [Notch homolog 1, translocation- 
associated (Drosophila)], K5 [keratin 5 
(KRT5)], K18, and PTEN (phosphatase and 
tensin homolog). For gene and primer infor-
mation, see Supplemental Material, Table 2 
(doi:10.1289/ehp.0901059.S1). For Western 
blot analysis, protein extracts were collected 
using either NE-PER or M-PER extraction 
reagents (Pierce, Rockford, IL), separated by 
SDS-PAGE, transferred to polyvinyl difluo-
ride membranes, and probed with anti-ΔNp63 
(Santa Cruz Biotechnology, Santa Cruz, CA) 
or anti-cytokeratin-18 (Sigma) followed by 
horseradish peroxidase (HRP)-conjugated sec-
ondary anti  bodies (Santa Cruz Biotechnology). 
Membranes were stripped and reprobed with 
anti-β-actin antibody (Calbiochem, San Diego, 
CA) followed by peroxidase-conjugated anti-
mouse (Santa Cruz Biotechnology). We used 
the ImageJ analysis program (version 1.24; 
National Institutes of Health 2007) for densi-
tometric analysis.
Immunocytochemical assessment of p63. 
We conducted immunocytochemistry for p63 
protein as described previously (Tokar et al. 
2005). Chamber slides (BD Biosciences) were 
coated with matrix (Tokar et al. 2005), and 
cells were plated and grown to sub  confluence, 
washed with phosphate-buffered saline, and 
fixed with a 1:1 solution of methanol:acetone 
for 2 min. For staining, cells were blocked 
with normal horse serum (1 hr), incubated 
with primary antibody (ΔNp63, 1:100, 1 hr), 
rinsed, incubated with HRP-conjugated anti-
mouse secondary antibody (1:500, 1 hr), 
and rinsed again. Staining was developed 
with ImmPACT DAB (diaminobenzidine) 
substrate (Vector Labs, Burlingame, CA), 
which produces a brown reaction product. 
Incubations were done at room temperature.
Xenograft tumor formation. Once biomark-
ers of carcinogenic transformation suggested 
that arsenic-induced carcinogenic conversion 
had occurred, arsenic-treated and control cells 
were injected into male nude mice (NCr-nu; 
Charles River Laboratory, Wilmington, MA). 
Mice were housed at the NCI-Frederick animal 
facility (Frederick, MD), and animal care was 
provided in accordance with the Public Health 
Service policy on the care and use of animals 
(Institute of Laboratory Animal Resources 
1996). For the first study, 1 × 106 total cells 
(floating spheres and adherent cells) were col-
lected and injected under the renal capsules 
of mice. In the second study, arsenite-treated 
floating cells were first separated from adher-
ent cells and 1 × 106 cells from each sub  group 
was injected subcutaneously (dorsal thoracic 
midline) into separate groups of mice. Animals 
were observed for tumor formation over a 
6-month period.
Statistical analysis. All data except tumor 
incidence represent mean and 95% confidence 
interval (CI). We used an unpaired Student’s 
t-test to compare arsenic-treated cells with 
untreated time-matched controls at individual 
time points. A Fisher’s exact test was used for 
tumor incidence data. In all cases, we consider 
a two-sided p < 0.05 significant. Sample sizes 
are given in figure legends.
Results
Arsenite-induced transformation of prostate 
SC/progenitor cells. MMP-9, an enzyme that 
when secreted digests extra  cellular matrix to 
aid in invasion and metastasis typical of cancer Tokar et al.
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cells (Morelli et al. 2004), including those 
produced by arsenic (Achanzar et al. 2002), 
showed marked increases between 16 and 
18 weeks of arsenic exposure in WPE-stem 
cells (Figure 1A). Marked increases in cellu-
lar invasion and CFE, which are additional 
characteristics of malignant cells, occurred 
concurrently (Figure 1B,C). In Matrigel, the 
WPE-stem cells formed ductal-like structures 
from single cells (Figure 1D), which is typical 
for NSCs from various tissues (Stingl et al. 
2006), but the arsenite-treated structures 
grew much faster, were much more branched, 
and hence appeared much more “aggres-
sive.” Together, these characteristics show 
that WPE-stem cells rapidly acquired a cancer 
pheno  type with arsenite exposure.
To establish malignant transformation, 
we inoculated cells under the renal capsules of 
mice. Arsenite-treated cells (As-CSCs) rapidly 
developed into highly pleomorphic tumors, 
with regional invasion and distant metasta-
ses that often dictated euthanasia in as little 
as 2–3 weeks. Tumors were highly undiffer-
entiated, highly malignant, and composed of 
immature epithelial- and mesenchymal-like 
cells (Figure 2A,B). Strong hetero  geneous 
staining for human K5 (Figure 2C), a marker 
of putative prostate epithelial SC/progenitor 
cells (Sawicki and Rothman 2002; Schalken 
and van Leenders 2003; van Leenders and 
Schalken 2001), supports a CSC-like nature 
and pluripotent cell of origination for these 
cancers. Tumors were very aggressive, showing 
invasion into renal parenchyma, abdominal 
muscle, adrenals, stomach, and small intes-
tine, and very frequently metastasized to the 
lungs. During the 6-month observation period, 
no tumors occurred in mice inoculated with 
untreated cells, whereas tumor incidence 
was > 40% after inoculation with As-CSCs 
(Figure 2D).
Arsenite causes overproduction of CSC-
like cells. A common characteristic of SCs in 
culture is the formation of floating “spheres” 
of viable cells (Dontu et al. 2003; Ghods et al. 
2007; Ponti et al. 2005; Tokar et al. 2005). 
Malignantly transformed As-CSCs showed 
a 230% increase in free-floating spheres over 
control (Figure 3A). After separating floating 
and adherent cells, secreted MMP-9 activity 
Figure 1. In vitro metrics of transformation in chronic arsenite-treated (5 µM) WPE-stem cells. (A) Secreted MMP-9 activity. Inset: representative zymogram 
(18 weeks). (B) Invasion; the A549 human lung carcinoma line was used as a positive control. (C) CFE; average numbers of colonies were 334 (control), 374 
(15 weeks), and 504 (18 weeks). (D) Ductal/glandular-like structures produced by WPE-stem cells (top) or As-CSCs (bottom). Bars = 50 µm. See “Materials and 
Methods” for details. Numerical data represent mean and 95% CI (n = 3). 
*p < 0.05 compared with control..
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Figure 2. Xenograft tumors from arsenite-transformed WPE-stem cells. (A, B) Representative sections showing the highly undifferentiated, pleomorphic nature of 
tumors after As-CSC inoculation. Areas of red blood cells indicative of probable vasculature disruption, including potential point of access, are visible; bars = 100 µm 
in A and 50 µm in B. B is a representative tumor arising from As-CSC inoculation at a higher magnification than A. (C) Immunohistologic section showing K5, a pros-
tate epithelial SC marker, in an As-CSC xenograft tumor, with strong, heterogeneous distribution in the epithelial and mesenchymal cells; bar = 25 µm. (D) Tumor 
incidence after inoculation under the renal capsule with control (n = 10) or arsenite-treated cells (18 weeks) (n = 17). 
*p < 0.05.
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from arsenite-exposed sphere cells was approxi-
mately 6 times that of either control (sphere or 
adherent) or arsenic-exposed adherent cells 
(Figure 3B). CFE of arsenite-exposed sphere 
cells was markedly elevated compared with 
adherent arsenite-exposed cells or either adher-
ent or sphere control cells (Figure 3C). The 
cells driving tumor formation were present 
only in arsenite-exposed spheres (Figure 3D), 
because when sphere cells were first separated 
from adherent cells and then inoculated into 
mice, only arsenite-exposed sphere cells rap-
idly produced highly pleomorphic cancers 
(Figure 2D). Mice inoculated with arsenite-
exposed adherent cells or pooled control cells 
showed no tumor formation when euthanized 
6 months after inoculation.
Self-renewal gene suppression and then 
reactivation during acquired CSC-like pheno-
type. We examined expression of several NSC 
self-renewal genes during arsenite-induced 
CSC phenotype acquisition. A remarkably 
consistent temporal pattern emerged in which 
NSC self-renewal gene expression was first lost 
and then reactivated with arsenite-induced 
acquired CSC-like phenotype (Figures 4 
and 5). As arsenite transformed NSCs into 
As-CSCs, the expression of self-renewal– 
associated genes p63 (Figure 4), BMI‑1, 
ABCG2, SHH, OCT‑4, and NOTCH‑1 
(Figure 5A–E) was first markedly suppressed 
(~ weeks 1–9) then reactivated (~ weeks 
9–18). Additionally, K5, a marker of undiffer-
entiated prostate SC/progenitor cells, showed 
the same pattern (Figure 5F). Conversely, 
K18, a marker of differentiated cells, showed 
the opposite trend of NSC self-renewal genes, 
first increasing and then returning to basal 
levels with transformation (Figure 6). This 
indicates that SC self-renewal was initially 
lost during early transformation, poten-
tially due to aberrant differentiation, and 
then regained with malignant transforma-
tion, consistent with distorted self-renewal 
common to CSCs (Pardal et al. 2003; Reya 
et al. 2001). This is consistent with CSC 
over  production induced by arsenite and the 
aggressive, highly pluripotent tumors formed 
by As-CSC cell inoculation. WPE-stem 
cells normally show homogeneous expres-
sion of prostate SC marker p63 (Tokar et al. 
2005), and immuno  cytochemical assessment 
showed that, although exposure-duration–
related expression changes occurred, expres-
sion remained homogeneously distributed 
throughout arsenite-induced transformation 
(Figure 4C), indicating that subpopulation 
selection did not occur.
Arsenite suppresses PTEN. PTEN, a 
tumor suppressor gene that modulates cell 
signaling pathways, has critical roles in SC dif-
ferentiation and is often inactivated in malig-
nancies (Di Cristofano and Pandolfi 2000). 
Starting at 9 weeks of arsenite exposure, a 
rapid, progressive decrease in PTEN expres-
sion occurred (Figure 7). This decrease 
coincided with the reactivation of the SC self-
renewal genes, indicating that these events are 
likely linked.
Discussion
Human arsenic exposure is linked to various 
UGS tumors, potentially including prostate 
cancers (Benbrahim-Tallaa and Waalkes 2008; 
IARC 2004), and emerging data indicate that 
arsenic may have human trans  placental carci-
nogenic activity (Smith et al. 2006). Similarly, 
prenatal arsenic exposure in mice induces or 
initiates neoplastic lesions throughout the UGS 
in adulthood (Waalkes et al. 2007, 2008), and 
because SCs may be an important target in 
trans  placental carcinogenesis (Anderson et al. 
2000), this suggests that UGS NSCs are key 
targets of arsenic. Using a model prostate epi-
thelial NSC population, we found that the SC 
phenotype appears to have a strong survival 
selection advantage toward arsenite (Tokar EJ, 
Waalkes MP, unpublished data), likely allow-
ing for survival in the face of continued carci-
nogenic insult. Based on these observations, in 
the present study an established human pros-
tate SC/progenitor cell line (Tokar et al. 2005) 
was chronically exposed to a non  toxic, environ-
mentally relevant concentration of arsenite (Pi 
et al. 2002) and rapidly (18 weeks) produced 
malignant transformant cells that showed mul-
tiple characteristics of CSCs, proved highly 
aggressive, and produced xenograft tumors 
indicative of a remarkably pluripotent cell of 
origin. This is compelling evidence that the 
metalloid can act directly upon a human SC/
progenitor population to initiate formation of 
CSC-like cells and provides unique insights 
into the very earliest period of arsenic carcino-
genesis. In contrast, the same level of arsen-
ite will induce transformation in its isogenic, 
mature hetero  geneous parental RWPE-1 cell 
line, but this takes 30 weeks, and the cells form 
much more differentiated tumors of epithelial 
origin with mature prostate qualities [Achanzar 
Figure 3. CSC-like characteristics in arsenite-treated and control cells. (A) Free-floating, viable spheres 
formed by arsenite-treated WPE-stem cells (top; bar = 100 µm) and sphere quantitation in control or 
arsenite-treated cells after malignant transformation (bottom). (B) Secreted MMP-9 activity from sphere 
and adherent cells from control and arsenite-treated cells after malignant transformation (bottom); the 
zymogram (top) shows MMP-9 activity. (C) Increased CFE in arsenite-transformed spheres after malignant 
transformation. Average numbers of colonies were 313 (control spheres), 637 (arsenite spheres), 326 (con-
trol adherent), and 479 (arsenite adherent). Data are percent increase compared with controls (mean and 
95% CI; n = 3). (D) Tumor incidence in mice (n = 10/group) inoculated with control cells, arsenite-exposed 
adherent sphere cells, or arsenite-exposed sphere cells. 
*p < 0.05 compared with control.
250
200
150
100
50
0
100
80
60
40
20
0
60
50
40
30
20
10
0
Control
Control
*
Arsenic Sphere
*
Adherent
Sphere Sphere Adherent Adherent
Total spheres
P
e
r
c
e
n
t
 
o
f
 
c
o
n
t
r
o
l
C
F
E
 
(
%
 
a
b
o
v
e
 
c
o
n
t
r
o
l
)
T
u
m
o
r
 
i
n
c
i
d
e
n
c
e
 
(
%
)
Control
Arsenic
700
600
500
400
300
200
100
0
700
600
500
400
300
200
100
0
M
M
P
-
9
 
a
c
t
i
v
i
t
y
 
(
%
 
o
f
 
c
o
n
t
r
o
l
)
Sphere
Control
1234567891 01 11 2
Arsenic Arsenic Control
Adherent
*
*
*Tokar et al.
112  v o l u m e  118 | n u m b e r 1 | January 2010  •  Environmental Health Perspectives
et al. 2002; see Supplemental Material, 
Table 1 (doi:10.1289/ehp.0901059.S1)]. As 
further examples, in vitro arsenic-transformed 
RWPE-1 cells show relatively modest increases 
in MMP-9 secretion (Achanzar et al. 2002) 
and relatively low invasiveness and colony for-
mation (Tokar EJ, Waalkes MP, unpublished 
data) compared with As-CSC cells. Thus, the 
WPE-stem cells transform much faster and 
show a much more aggressive and totipotent 
phenotype (present study) compared with 
mature hetero  geneous isogenic parental trans-
formed cells (Achanzar et al. 2002). In accord 
with the CSC theory (Gisselsson 2007; Pardal 
et al. 2003; Reya et al. 2001) and the multi  step 
Figure 4. Expression of p63, an NSC gene associated with maintenance and self-renewal, during arsenite-induced malignant transformation of WPE-stem cells. 
p63 transcript (A) and protein (B) levels decreased at 9 weeks but increased again to control levels by point of malignant transformation (18 weeks). Data rep-
resent mean and 95% CI (n = 3–6). (C) Immunocytochemical images for p63 consistent with Western blots show that WPE-stem cells remained a homogeneous 
population during transformation; bars = 50 µm. 
*p < 0.05 compared with time-matched controls (A) or baseline levels (B).
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Figure 5. Expression of NSC genes associated with maintenance, self-renewal, and differentiation during arsenite-induced malignant transformation of WPE-stem 
cells. Transcript levels for BMI-1 (A), ABCG2 (B), SHH (C), OCT-4 (D), NOTCH-1 (E), and K5 (F) all show the same loss then reactivation of expression as that seen 
with p63, indicating that a common pattern of alterations in an NSC-like transcription program involving self-renewal occurs during arsenite-induced progression 
of NSCs to CSCs. Data represent mean and 95% CI (n = 3–6). 
*p < 0.05 compared with time-matched controls.
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carcinogenesis theory (Vogelstein and Kinzler 
1993), the stage of differentiation determines 
not only the number of genetic alterations nec-
essary for carcinogenic transformation but also 
dictates the aggressiveness of resulting tumors 
(Gisselsson 2007). NSCs, with their permissive 
state of differentiation, would need much fewer 
molecular transformational events, whereas 
mature cell populations would require more 
numerous alterations (Gisselsson 2007). The 
much more rapid transformation and resul-
tant aggressive, pluripotent phenotype seen in 
arsenite-transformed As-CSC cells compared 
with the transformed mature, parental cells 
(Achanzar et al. 2002) is consistent with this 
“permissive plasticity” concept of SCs in chem-
ical carcino  genesis theory (Gisselsson 2007).
The arsenic biomethylation capacity of 
WPE-stem cells is unknown. However, the 
parental RWPE-1 cells only very poorly 
methylate arsenic (Benbrahim-Tallaa et al. 
2005). Whether the transformative agent of 
WPE-stem was inorganic arsenic, a methylated 
metabolite, or some combination remains to 
be determined.
CSCs isolated from advanced can-
cers typically reinitiate their tumor of ori-
gin (Al-Hajj et al. 2003; Singh et al. 2004). 
The remarkably low level of differentiation 
of As-CSC–produced xenograft tumors is 
perhaps a result of being transformed in the 
absence of surrounding mature cell signals 
directing them to a particular cancer based 
on tissue of origin. Such a minimally differ-
entiated status is rare in adulthood tumors 
but common in some childhood tumors 
(e.g., nephro  blastomas, teratomas) that are 
derived from immature embryonal-like cells 
(Gisselsson 2007). This primordial epithe-
lial/mesenchymal histo  pathology, coupled 
with strong hetero  geneous staining for epi-
thelial SC markers (K5; Schalken and van 
Leenders 2003), suggests that the As-CSC 
hetero-transplantation tumors developed 
from highly pluripotent cells, allowing diver-
gent differentiation toward both epithelial 
and mesenchymal components. The rapid 
progression and high aggressiveness suggest 
that arsenite quickly triggered acquisition of 
a malignant CSC-like phenotype consistent 
with a loss of self-renewal and differentia-
tion control. Similarly, pleomorphic uterine 
carcino  sarcomas, although not associated 
with arsenic exposure in humans, were once 
thought to be “collision” tumors but are now 
thought to derive from a single SC popula-
tion that has acquired the ability to undergo 
aberrant, divergent differentiation, producing 
both mesenchymal and epithelial cancerous 
components (McCluggage 2002). Our data 
indicate that arsenite has instilled a similar 
potential into As-CSC cells. Furthermore, 
very recently we found that when injected 
intra  venously into mice, As-CSC cells formed 
highly pleomorphic malignancies in lung, 
liver, and skin (Tokar EJ, Waalkes MP, 
unpublished data). This provides significant 
support to the concept that arsenic has trans-
formed human NSC/progenitor cells into 
CSC-like cells and adds credence to this as 
a plausible component of the mechanism of 
arsenic carcinogenesis.
Many cultured NSC or CSC lines form 
free-floating spherical clusters of viable cells 
containing a preponderance of the NSCs 
or CSCs (Dontu et al. 2003; Ghods et al. 
2007; Ponti et al. 2005; Tokar et al. 2005). 
Only sphere cells from arsenite-transformed 
WPE-stem cells formed xenograft tumors. This 
strongly supports our contention that arsenite 
has triggered CSC-like formation from pheno-
typically normal SCs because tumor-forming 
CSCs derived from advanced cancers typically 
reside in these spheres (Ghods et al. 2007). 
Furthermore, arsenite produced an over-
abundance of CSC-like cells, primarily in the 
spheres, potentially accounting for the rapid 
formation, toti  potent nature, and remark-
able aggressiveness of the resulting xenograft 
tumors. In vivo arsenic alters skin SC popu-
lation dynamics, eventually enhancing skin 
carcinogenesis coinciding with increased CSCs 
in epidermal carcinomas (Waalkes et al. 2008). 
Thus, arsenic appears to target SC populations 
both in vitro (present study; Patterson and Rice 
2007) and in vivo (Waalkes et al. 2008), dis-
torting SC dynamics and precipitating CSC 
over  production. Whether other carcinogens 
act in a similar fashion is an important ques-
tion that requires further investigation.
NSCs and CSCs share fundamental prop-
erties, including self-renewal capacity, which 
is typically dysregulated in oncogenesis (Pardal 
et al. 2003; Reya et al. 2001). In this regard, 
a remarkably consistent “U-shaped” temporal 
response occurred with several SC self-renewal 
genes (p63, BMI‑1, ABCG2, SHH, OCT‑4, 
and NOTCH‑1) during arsenic-induced malig-
nant transformation, with an initial suppres-
sion followed by reactivation. p63 is essential 
for SC self-renewal and proliferation within the 
prostate and other tissues (Senoo et al. 2007; 
Signoretti et al. 2005). BMI-1 is required for 
self-renewal of both NSCs and CSCs in the 
prostate (Lessard and Sauvageau 2003; Pardal 
et al. 2003). In several tissues SHH promotes 
SC self-renewal, whereas aberrant activation is 
implicated in carcinogenesis (Reya et al. 2001; 
Ruiz i Altaba et al. 2002). ABCG2 plays a 
clear role in maintaining SC populations and 
is a prostate NSC or CSC marker (Huss et al. 
2005; Zhou et al. 2001). OCT‑4 is a pluripo-
tency gene required for NSC self-renewal and 
maintenance that is often activated in carcino-
genesis (Hochedlinger et al. 2005). The Notch 
signaling pathway regulates NSC self-renewal 
Figure 6. K18 expression during arsenic-induced malignant transformation of WPE-stem cells. (A) K18 tran-
script levels during chronic arsenic exposure show early, marked increases followed by a decrease back 
toward control levels by the time of malignant transformation (18 weeks; n = 6). (B) Quantitative analysis of 
K18 protein levels during malignant transformation (n = 3) shows that the trend is consistent with transcript 
levels and is opposite that seen for SC markers (Figures 4 and 5). Data represent mean and 95% CI.
*p < 0.05 compared with time-matched controls (A) or baseline levels (B).
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Figure 7. PTEN expression during arsenite-induced 
malignant transformation of WPE-stem cells. PTEN 
transcript levels show a progressive and marked 
decrease starting at 9 weeks of arsenite treatment. 
Data represent mean and 95% CI (n = 6).
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and differentiation and is frequently dys-
regulated in oncogenesis (Artavanis-Tsakonas 
et al. 1999; Pardal et al. 2003). In the prostate, 
Notch-1 is a marker for SC/progenitor cells, is 
required for normal development, and has 
been shown to function as both an oncogene 
and tumor suppressor during prostate carcino-
genesis (Leong and Gao 2008). Additionally, 
for keratins, K5 is a marker for undifferenti-
ated basal SCs, whereas K18 is a marker of dif-
ferentiated cells, and K5 expression increases 
during carcinogenesis (Sawicki and Rothman 
2002; Schalken and van Leenders 2003). The 
remarkably consistent trend in these criti-
cal self-  renewal/differentiation genes during 
WPE-stem transformation suggests that arsen-
ite instilled aberrant self-renewal and differ-
entiation capabilities as these cells acquired a 
malignant CSC phenotype. Intriguingly, this 
trend is consistent with that seen when LSCs 
are formed by introduction of the mixed lin-
eage leukemia (MLL‑AF9) gene into hemato-
poietic committed progenitor cells (Krivtsov 
et al. 2006). A group of self-renewal genes 
highly expressed in HSCs is lost in committed 
progenitors but reactivated in LSCs initiated 
by introduction of the MLL-AF9 fusion pro-
tein (Krivtsov et al. 2006). Likewise, reactiva-
tion of an SC-like genetic program in adult 
hematopoietic cells can introduce aberrant 
self-renewal characteristics of CSCs (Wong 
et al. 2008). Thus, distortion of an NSC 
self-renewal-associated signature drives these 
hematopoietic cells toward LSC phenotype 
(Krivtsov et al. 2006; Wong et al. 2008) and 
clearly shows that this trend is not arsenic spe-
cific, but potentially common during the pro-
cess of CSC formation. Together with prior 
work (Krivtsov et al. 2006; Wong et al. 2008), 
the present data suggest that sequential distor-
tion of self-renewal–associated genes is critical 
to CSC formation.
During arsenite-induced transformation 
and formation of As-CSCs, the dramatic 
decrease in PTEN expression coincided with 
the reactivation of self-renewal genes and 
acquisition of malignant phenotype. Poor 
prostatic PTEN expression increases SC-like 
cells and causes cancer initiation (Signoretti 
and Loda 2007) and in prostate cancer cells 
increases sphere-forming ability and xeno  graft 
sphere cell tumorigenicity (Dubrovska et al. 
2009). Furthermore, loss of PTEN enhances 
self-renewal capacity of SCs without dra-
matically altering pluripotency (Groszer et al. 
2006). PTEN expression maintains HSCs in a 
quiescent state, and its deletion leads to HSC 
depletion and leukemia formation enriched 
for LSCs (Yilmaz et al. 2006; Zhang et al. 
2006). The loss of PTEN provides a plausible 
mechanism through which As-CSC cells reac-
tivate self-renewal, although dysregulated, and 
yet maintain and potentially distort multi-
potential differentiation capacity.
Conclusion
Our data support the hypothesis that invokes 
emergence of CSCs from NSCs as a primal 
initiating event in oncogenesis (Bapat 2007; 
Pardal et al. 2003; Reya et al. 2001), at least 
for arsenic. Indeed, arsenite directly targeted 
the human WPE-stem line, transforming them 
into a highly aggressive CSC-like pheno  type. 
Once transformed, these cells possess multiple 
CSC-like charac  teristics, including enhanced 
self-renewal capacity, competency to proliferate, 
clonogenicity, and, perhaps most important, 
the ability to initiate highly aggressive, imma-
ture, pluripotent tumors in vivo. The truly 
stunning capacity to rapidly produce highly 
pleomorphic tumors in xenograft studies and 
the fact that only cells from the arsenite-treated 
spheres formed tumors, together with strong 
evidence that CSCs reside in simi  lar spheres 
derived from advanced cancers (Ghods et al. 
2007), support a direct acquisition of malig-
nant CSC-like phenotype from NSC/progeni-
tor cells triggered by arsenic. Additionally, our 
data fortify the emerging concept that the loss 
and subsequent reactivation of SC self-renewal 
are critical during malignant transformation of 
SCs, as appears to be the case with leukemias 
(Bapat 2007; Krivtsov et al. 2006; Rossi et al. 
2008; Wong et al. 2008).
Overall, this study expands our under-
standing of the carcinogenic potential of 
arsenic, a common environmental contami-
nant (IARC 2004), by indicating that it can 
directly target SCs for carcinogenic transfor-
mation. Millions of people are exposed, likely 
throughout their entire lifetime, to unhealthy 
levels of arsenic in drinking water (IARC 
2004). Arsenic is clearly a trans  placental 
carcinogen in rodents (Waalkes et al. 2007) 
and probably in humans (Smith et al. 2006), 
and SCs are likely key targets in in utero life-
stage susceptibility to chemical carcino  genesis 
(Anderson et al. 2000). Therefore, the abil-
ity to malignantly transform NSCs could be 
of major mechanistic significance in arsenic-
exposed human populations.
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